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DOI 10.1016/j.ccr.2011.06.016SUMMARYPolycomb Repressive Complexes (PRC1 and PRC2)-mediated epigenetic regulation is critical for maintain-
ing cellular homeostasis. Members of Polycomb Group (PcG) proteins including EZH2, a PRC2 component,
are upregulated in various cancer types, implicating their role in tumorigenesis. Here, we have identified
several microRNAs (miRNAs) that are repressed by EZH2. These miRNAs, in turn, regulate the expression
of PRC1 proteins BMI1 and RING2. We found that ectopic overexpression of EZH2-regulated miRNAs atten-
uated cancer cell growth and invasiveness, and abrogated cancer stem cell properties. Importantly, expres-
sion analysis revealed an inverse correlation between miRNA and PRC protein levels in cell culture and
prostate cancer tissues. Taken together, our data have uncovered a coordinate regulation of PRC1 and
PRC2 activities that is mediated by miRNAs.INTRODUCTION
Polycomb group (PcG) proteins are evolutionarily conserved
regulators of gene silencing important in metazoan development
(Surface et al., 2010), stem cell pluripotency (Pereira et al., 2010),
and X chromosome inactivation (Cao et al., 2002;Margueron and
Reinberg, 2011). PcG proteins form multiprotein repressive
complexes called PRCs. Both PRC1 and PRC2 play a critical
role in the maintenance of normal and cancer stem cell pop-
ulations (Ezhkova et al., 2009; Lukacs et al., 2010; Pietersen
et al., 2008). Dysregulation of PcG proteins can contribute toSignificance
Polycomb group (PcG) proteins are chromatin-modifying com
tant role in determining cell fate. PcG proteins form two majo
Polycomb Repressive Complex 2 (PRC2). PRC2 methylates hi
lates PRC1 to enact gene silencing at target genes. Employing
we demonstrate that PRC2 and PRC1 coordinate their function
activity in cancer leads to repression of these microRNAs, and
pose that key microRNAs link PRC2 to PRC1 forming an intega number of human diseases, most notably, cancer (Bracken
and Helin, 2009; Margueron and Reinberg, 2011).
Key components of the human PRC2 include the histone
methyltransferase Enhancer of Zeste Homolog 2 (EZH2), and
its binding partners, Embryonic Ectoderm Development (EED)
and Suppressor of Zeste 12 (SUZ12), which function as a multi-
subunit complex that trimethylates histone H3K27. PRC2 is
thought to be recruited to target genomic loci by long noncoding
RNAs (ncRNAs) such as HOTAIR (Gupta et al., 2010; Kaneko
et al., 2010; Rinn et al., 2007). EZH2, which is the enzymatic
component of PRC2, is elevated in aggressive forms of prostateplexes that regulate epigenetic silencing and play an impor-
r complexes, Polycomb Repressive Complex 1 (PRC1) and
stone H3 on lysine27 (H3K27), a chromatin mark that stimu-
in vitro and in vivo cancer models and human tumor studies,
s through regulation of specificmicroRNAs. Increased PRC2
subsequent increase of PRC1 components. Thus, we pro-
ral regulatory axis of the epigenetic silencing machinery.
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microRNAs Link PRC2 to PRC1and breast cancer (Kleer et al., 2003; Varambally et al., 2002), as
well asmultiple other solid tumors (Matsukawa et al., 2006; Sudo
et al., 2005). Loss of microRNA (miRNA)-101, has been shown to
be one mechanism that leads to elevated EZH2 and PRC2
activity in tumors (Cao et al., 2010; Chiang et al., 2010; Friedman
et al., 2009; Varambally et al., 2008; Wang et al., 2010). Also,
miR-26a was reported to target EZH2 in cancer and myogenesis
(Lu et al., 2011;Wong and Tellam, 2008). Accumulating evidence
suggests that increased activity of PRC2 is oncogenic as
measured by cell proliferation (Bracken et al., 2003; Varambally
et al., 2002), cell invasion (Cao et al., 2008; Kleer et al., 2003),
anchorage-independent growth (Bracken et al., 2003; Kleer
et al., 2003), maintenance of tumor-initiating cells, tumor xeno-
graft growth (Yu et al., 2007b), and metastasis in vivo (Min
et al., 2010) .
A key collaborator of PRC2 in epigenetic silencing is human
PRC1, which comprises B lymphoma Mo-MLV insertion region
1 (BMI1), RING1 (also known as RING1A or RNF1) and RING2
(also known as RING1Bor RNF2), and functions as amultiprotein
complex to ubiquitinate histone H2A at lysine 119 (uH2A) (Cao
et al., 2005; Wang et al., 2004). The prevailing hypothesis is
that PRC2-mediated trimethylation of H3K27 recruits PRC1 to
gene loci, which enacts chromatin condensation and epigenetic
silencing of target genes (Bracken and Helin, 2009). Like PRC2
component EZH2, BMI1 and RING2 have been shown to be
elevated in a number of tumor types (Glinsky et al., 2005; Sa´n-
chez-Beato et al., 2006) and regulate self-renewal of embryonic
stem cells and cancer stem cells (Galmozzi et al., 2006; Valk-
Lingbeek et al., 2004). The mechanism of how PRC2 and
PRC1 coordinate their functions is still unclear. In this study,
we sought to explore the regulatory axis between PRCs and
whether miRNAs mediate the synergy between the two
complexes.
RESULTS
PcG Proteins Are Regulated by miRNAs
Previously, it has been reported that EZH2, the methyltransfer-
ase subunit of the PRC2 complex, is repressed by miR-101
(Friedman et al., 2009; Varambally et al., 2008) and miR-26a
(Lu et al., 2011; Wong and Tellam, 2008). We hypothesized
that PcG proteins (comprising the mammalian PRC complexes)
may in general be regulated by miRNAs. To test this hypothesis,
we knocked down Dicer, a key protein required for miRNA pro-
cessing, by employing Dicer-specific siRNA duplexes. By immu-
noblot analysis, we found that PRC2 proteins EZH2, EED, and
SUZ12, and PRC1 proteins BMI1 and RING2 were increased
significantly by three different Dicer siRNA duplexes (Figure 1A;
see Figure S1A available online). These experiments support the
general notion that miRNAs function to repress PcG expression.
Identification of EZH2-Regulated miRNAs
To explore miRNAs regulated by PRC2 globally, we knocked
down EZH2 in DU145 prostate cancer cells with a validated
siRNA targeting EZH2 and monitored miRNA expression with
Illumina BeadChips. In parallel, we compared these miRNA
profiles with DU145 cells relative to four benign epithelial cell
lines of either prostate (PrEC and RWPE) or breast (H16N2
and HME) origin. We primarily observed miRNAs that were188 Cancer Cell 20, 187–199, August 16, 2011 ª2011 Elsevier Inc.decreased in cancer cells relative to benign that are targets of
repression by EZH2, and thus PRC2. We found 63 miRNAs
that were downregulated in DU145 cells compared with the
normal cell lines, and inhibition of EZH2 by knockdown restored
expression of these miRNAs (Figure 1B; Table S1). Similarly, the
expression levels of these 63 miRNAs were downregulated in
breast cancer cells BT-549 and SKBr3 compared with breast
benign epithelial cells H16N2 and HME (Figure 1B; Table S1)
UsingmiRNA target analysis (www.targetscan.org), we identified
14 miRNAs as top candidates with the following properties: (1)
upregulated by EZH2 knockdown in DU145 cancer cells which
express high levels of PRC2; (2) higher in benign cell lines
compared with DU145 cells, and (3) predicted to bind to the 30
untranslated region (UTR) of target PRC1 components based
on TargetScan (Figure 1C). Thirteen of the 14 miRNAs meeting
these criterion fell into several known miRNAs clusters and fami-
lies, including miR-200b and miR-200c in the miR-200 family,
which has previously been reported to repress BMI1 (Shimono
et al., 2009; Wellner et al., 2009). Of the 14 miRNAs, only miR-
203, which is also known to target BMI1 (Wellner et al., 2009),
does not belong to any known cluster or family (Figure S1B).
EZH2-Regulated microRNAs Inhibit Expression of PRC1
Proteins BMI1 and RING2
To pinpoint the specific miRNAs that target PRC1 (out of the 14
that were nominated by computational approaches) (Figure 1C),
we overexpressed each of them in BT-549 and DU145 cancer
cell lines andmonitored EZH2, BMI1, and RING2 protein expres-
sion (Figure 2A; Figure S2A). Of these, miR-181a, b decreased
RING2 protein levels, miR-203 decreased BMI1 protein levels
while miR-200b,c decreased both BMI1 and RING2 (Figure 2A).
Attenuation of these PRC1 members resulted in decreased glo-
bal ubiquityl-H2A, a known PRC1 substrate and mark of gene
repression. Furthermore, PRC1 targets including p16INK4A
(Jacobs et al., 1999a) and p21 (Waf1/Cip) (Fasano et al., 2007)
were derepressed (Figure 2A). Several of the miRNAs com-
putationally predicted to inhibit PRC1 failed to do so by overex-
pression including miR-17, miR-19b, and others (Figure S2A).
Similar to protein levels, real-time qPCR showed miR-181a,b
and miR-200b,c decreased RING2 transcript levels and miR-
200b,c and miR-203 decreased BMI1 transcript levels in
BT-549 cells (Figure 2B). As expected, overexpressing miR-
200b or miR-203 decreased BMI1 occupancy on known PRC1
target gene p16, p19 (Jacobs et al., 1999b), p21, and HoxC13
(Cao et al., 2005) regions (Figure S2B).
To further corroborate our miRNA overexpression studies, we
also extinguished expression of miRNAs using antagomiRs
(Kru¨tzfeldt et al., 2005). Consistent with our predictions, anta-
gomiR-200b, antagomiR-200c, and antagomiR-203 increased
BMI1 protein levels, while antagomiR-181a, antagomiR-181b,
antagomiR-200b, and antagomiR-200c increased RING2 pro-
tein levels in H16N2 cells (Figure 2C).
To evaluate whether these miRNAs directly bind to the 30 UTR
of BMI1 or RING2, we cloned the predicted binding sites of the
wild-type or mutant 30 UTR into a luciferase reporter system
and cotransfected them with miRNA expression vectors into
BT-549 cells (Figure 2D; Figures S2C–S2F). As expected, inhibi-
tion of luciferase activity was observed in cells transfected with
constructs containing wild-type binding sites but not the mutant
AC
B
Figure 1. PcG Proteins Are Regulated by
miRNAs
(A) Knockdown of Dicer in DU145 and BT-549 cells
by three different Dicer-specific duplexes and PcG
protein expression was assessed.
(B) miRNA profiling of DU145 prostate cancer cells
in which EZH2 was knocked down compared with
DU145 cancer cells relative to benign cells HME,
PrEC, RWPE, and H16N2. Shades of red represent
increased gene expression while shades of green
represent decreased expression.
(C) A Venn diagram depicting 14miRNAs that were
upregulated by EZH2 knockdown, had high
endogenous levels in normal cells, and were pre-
dicted to target PRC1 proteins.
See also Figure S1 and Table S1.
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microRNAs Link PRC2 to PRC1constructs. The RING2 30 UTR reporters were downregulated by
miR-181a, miR-181b, miR-200b, and miR-200c while the BMI1
30 UTR reporters were downregulated by miR-200b, miR-200c,
and miR-203 (Figure 2D).
We next determined whether the miRNAs that regulate PRC1
were directly regulated by PRC2 in BT-549 and DU145 cells.
Cells were transfected with either a validated EZH2 siRNA or
miR-101 (both of which target and downregulate the PRC2),
and expression levels of target miRNAs were measured by
real-time PCR. miR-181a, miR-181b, miR-200a, miR-200b,
miR-200c, and miR-203 expression levels were increased in
EZH2 siRNA or miR-101-transfected cells. Expression of
miRNAs miR-217 and miR-219, two control microRNAs not pre-
dicted to be regulated by EZH2, were not altered (Figure 3A).Cancer Cell 20, 187–19Further, we observed similar expression
changes in these microRNAs upon sta-
ble overexpression of miR-101 or EZH2
shRNA in DU145 and SKBr3 cells (Fig-
ure S3A). Also we observed that miR-
101 was increased in DU145 cells in
which EZH2 was stably knocked down,
suggesting the existence of feedback
regulation between EZH2 and miR-101.
In contrast, overexpression of EZH2, but
not EZH2DSET (which is missing its cata-
lytic SET domain), decreased miR-181a,
miR-181b, miR-200a, miR-200b, miR-
200c, and miR-203 levels in H16N2 cells
(Figure S3B).
Next, we treated DU145 cells with the
global histone methylation inhibitor, dea-
zaneplanocin A (DZNep), that depletes
PRC2 and thus attenuates H3K27me3
(Tan et al., 2007). Interestingly, DZNep
treatment led to derepression of the puta-
tivePRC2-targetedmiRNAs includingmiR
181a,b, miR-200a,b,c, and miR-203
(Figure 3B). This effect was both concen-
tration and incubation time dependent.
Control microRNAs, miR-217, miR-219,
and miR-21 were not affected by DZNep
treatment.In addition to DZNep, we evaluated other chemical inhibitors of
epigenetic pathways. As HDAC activity is essential for EZH2
function (Cao et al., 2008; Kleer et al., 2003), and EZH2 directly
or indirectly facilitates DNAmethylation (Vire´ et al., 2006), we pre-
dicted that treatment with the HDAC inhibitor suberoylanilide
hydroxamic acid (SAHA) and/or the DNA methylation inhibitor
5-aza-20-deoxycytidine (5-aza-dC) would inhibit EZH2-mediated
epigenetic modifications, leading to an increase in miRNA
expression. Treatment of BT-549 and DU145 cells with 5-aza-
dC or SAHA alone or in combination, resulted in a marked incre-
ase in miR-181a,b, miR-200a,b,c, andmiR-203 expression, sug-
gesting epigenetic regulation of these microRNAs (Figure 3C).
Importantly, when we overexpressed EZH2 by adenovirus in
DZNep or SAHA and 5-aza-dC-treated DU145 cells, EZH2 could9, August 16, 2011 ª2011 Elsevier Inc. 189
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Figure 2. PRC2-RegulatedmiRNAsRepress
PRC1 Proteins BMI1 and RING2
(A) Overexpression of indicated miRs in DU145
and BT-549 cells and expression of PRC compo-
nents, PRC2 histone mark H3K27me3, PRC1
target histone mark ubiquityl-H2A and indicated
genes by immunoblot analysis. b-actin and total
H3 were used as loading controls.
(B) As in (A), except transcript level was assessed
in BT-549 by qPCR.
(C) Transfection of indicated antagomiRs (anti-
miR) in H16N2 cells and immunoblot analysis for
BMI1 and RING2. b-actin was used as a loading
control.
(D) TargetScan analysis depicting potential
binding sites for EZH2-regulated miRNAs in the 30
UTR of BMI1 and RING2. Luciferase reporter
assays with wild-type or mutant 30 UTR constructs
of BMI1 or RING2 demonstrate that miR-181a,
miR-181b, miR-200b, miR-200c, and miR-203
repress BMI1 and/or RING2 activity.
All bar graphs are shown with ± SEM. See also
Figure S2.
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microRNAs Link PRC2 to PRC1completely abolish DZNep-mediated miRNA upregulation (Fig-
ure S3C), and partially decreased SAHA and 5-aza-dC-mediated
miRNA upregulation (Figure S3D) presumably because SAHA
and 5-aza-dC also inhibited HDAC and DNMT activities.
To confirm that EZH2 regulates these microRNAs by epige-
netic repression, we performed chromatin immunoprecipitation
(ChIP) assays with anti-H3K27me3, EZH2 and BMI1 antibodies
in BT-549 cells. Interestingly, H3K27me3 and EZH2 occupied
the PRC2-regulated miRNAs regions as expected. In addition,
BMI1 also occupied these regions (Figure S3E), suggesting190 Cancer Cell 20, 187–199, August 16, 2011 ª2011 Elsevier Inc.that a negative feedback system between
PRC2-regulated miRNAs and PRC1 may
exist. Furthermore, an EZH2-specific
siRNA (Figure S3F) or treatment with
5-aza-dC and SAHA, either alone or in
combination (Figure 3D), markedly decre-
ased the H3K27me3 occupancy in these
regions.
EZH2-RegulatedmiRNAs Attenuate
Growth, Invasiveness, and Self-
Renewal of Cancer Cells
Because EZH2 has been shown to
repress several tumor suppressor genes
(Cao et al., 2008; Chen et al., 2005; Fujii
et al., 2008; Min et al., 2010; Yu et al.,
2007b, 2010), we postulated that the
EZH2-regulated microRNAs also func-
tioned as tumor suppressors. Consistent
with this hypothesis, overexpression of
either miR-181a, miR-181b, miR-200a,
miR-200b, miR-200c, or miR-203 mark-
edly attenuated BT-549 and DU145 cell
proliferation to levels similar to that of
cells transfected with EZH2 siRNA, or
cells overexpressing miR-101 (Figure 4A*p < 0.001, **p < 0.01; Figure S4A). Likewise, overexpression
of either miR-181a, miR-181b, miR-200a, miR-200b, miR-
200c, or miR-203 inhibited the in vitro invasive potential of
BT-549 and DU145 cells through modified Boyden chambers
coated withMatrigel (Figure 4B, *p < 0.005, **p < 0.02). However,
overexpressing EZH2-repressed miRNAs had no effect on the
invasiveness of RWPE-UBE2L3-KRAS and RWPE-SLC45A3-
BRAF stable cells, in which fusion proteins UBE2L3-KRAS
(Wang et al., 2011) and SLC45A3-BRAF (Bonci et al., 2008; Pal-
anisamy et al., 2010) confer neoplastic properties to RWPE cells
AB D
C
Figure 3. PRC2 Silences Multiple miRNAs by Epigenetic Mechanisms
(A) Taqman miRNA qPCR analysis of indicated miRs in BT-549 and DU145 cells in which EZH2 was knocked down using siRNA or miR-101 (a microRNA which
targets EZH2). Quantitative microRNA levels were normalized against U6.
(B) As in (A), except DZNep at two different doses and time points was incubated with DU145 cells.
(C) As in (A), except SAHA and/or 5-aza-dC was used in BT-549 and DU145 cells.
(D) ChIP-qPCR analysis of H3K27me3 at indicated genes and microRNAs in BT-549 cells treated with SAHA and/or 5-aza-dC.
All bar graphs are shown with ± SEM. See also Figure S3.
Cancer Cell
microRNAs Link PRC2 to PRC1(Figure S4B), suggesting that EZH2-repressed miRNAs miR-
181a,b, miR-200b,c, and miR-203 may inhibit cell invasion
through acting on PRC1 proteins. However, EZH2-repressed
miRNAs still decreased RWPE-UBE2L3-KRAS and RWPE-
SLC45A3-BRAF proliferation (Figure S4C), consistent with a crit-
ical role of PcG proteins in cell growth.
To investigate whether miR-181a, miR-181b, miR-200a, miR-
200b, miR-200c, or miR-203 inhibit anchorage-independentgrowth, we performed soft agar colony formation assays. Similar
to miR-101 and EZH2 knockdown controls, overexpression of
miR-181a, miR-181b, miR-200a, miR-200b, miR-200c, and
miR-203 markedly suppressed DU145 colony formation (Fig-
ure 4C, *p < 0.001, **p < 0.01). Next, we evaluated the ability of
DU145 to form prostatospheres in sphere-promoting cell media.
This assay serves as a surrogate measure of stem cell-like
phenotypes, and cells that are able to form spheres haveCancer Cell 20, 187–199, August 16, 2011 ª2011 Elsevier Inc. 191
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Figure 4. PRC2-Mediated Regulation of microRNAs Potentiates the Cancer Cell Phenotype
(A) Overexpression of PRC2-regulatedmiRNAs, but not control miR-217 ormiR-219, inhibited BT-549 cell proliferation. EZH2 siRNA andmiR-101 overexpression
were positive controls and miR-217 and miR-219 overexpression were negative controls. *p < 0.001, **p < 0.01. (Student’s t test).
(B) Overexpression of PRC2-regulated miRNAs decreased BT-549 and DU145 cell invasion in vitro. *p < 0.01. (Student’s t test).
(C) Overexpression of PRC2-regulated miRNAs suppressed DU145 anchorage-independent growth in soft agar. *p < 0.01. (Student’s t test).
(D) Overexpression of EZH2-regulated miRNAs decreased prostatosphere formation by DU145 cells. *p < 0.01. (Student’s t test). Representative images of
prostatospheres (scale bar: 100 mm) were shown in the inset.
(E) qPCR analysis demonstrating EZH2, BMI1 and RING2 transcript levels were higher in spheres compared with monolayer culture, while miR-101, miR-181a,b,
miR-200a,b,c, and miR-203, but not miR-217 or miR-219, were lower in spheres compared with monolayers. Expression level of each gene was normalized to
GAPDH or U6 and normalized to corresponding monolayer cultured cell line.
(F) qPCR analysis showing EZH2, BMI1 and RING2 levels were higher in sorted CD24-/CD44+ DU145 and RWPE cells compared with the unsorted population,
while miR-101, miR-181a,b, miR-200a,b,c, and miR-203, but not miR-217 or miR-219, were lower in CD24-/CD44+ DU145 and RWPE cells compared with an
unsorted population.
(G) Genes regulated by EZH2-repressed miRNAs cluster into multiple functional concepts. BT-549 and DU145 cells were transfected with EZH2-repressed
miRNAs followed by gene expression profiling and Molecular Concepts analysis. Each node represents a molecular concept or set of biologically related
genes. miR-101, miR-181a, miR-181b, miR-200a, miR-200b, miR-200c, and miR-203 (miRNA signatures, purple for BT-549, orange for DU145) were enriched
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microRNAs Link PRC2 to PRC1enhanced stem cell characteristics (Lawson et al., 2007). We
found that miR-181a, miR-181b, miR-200a, miR-200b, miR-
200c, and miR-203 overexpression, as well as miR-101 overex-
pression and EZH2 siRNA controls, significantly inhibited the
ability of DU145 cells to form spheres in this assay (Figure 4D,
*p < 0.001, **p < 0.01). Intriguingly, several genes implicated in
pluripotency and cellular reprogramming by induced pluripo-
tency, such as Klf4, Sox2, and c-Myc, weremarkedly downregu-
lated by miR-200b, miR-200c, and miR-203, and marginally
decreased by miR-101, miR-181a, miR-181b, and miR-200a
expression, but not bymiR-217ormiR-219 controls (Figure S4D).
Relative to the human embryonic stem cell H7, BT-549 and
DU145 cancer cells have comparable expression levels of iPS
factors and PcG proteins (Figure S4E).
Next, we measured expression levels of EZH2, BMI1, RING2,
and key microRNAs relevant to this study in spheres and mono-
layers. In BT-549, SKBr3, DU145, and PC3 cells, we observed
that EZH2, BMI1, and RING2 levels were higher in spheres
than in monolayers; conversely miR-101, miR-181a, miR-181b,
miR-200a, miR-200b, miR-200c, and miR-203 levels were lower
in spheres than in monolayers (Figure 4E). Using DU145 and
RWPE parental cell lines, we employed flow cytometry to isolate
cells with high expression of the CD44 surface antigen and low
expression of the CD24 surface antigen (CD24-/CD44+), a cell
population enriched for stem cell-like phenotypes (Hurt et al.,
2008). We measured EZH2, BMI1, RING2, and miRNA levels in
CD24-/CD44+ cells compared with total, unsorted cells. We
observed that EZH2, BMI1, and RING2 levels were increased
in CD24-/CD44+ cells, but miR-101, miR-181a, miR-181b,
miR-200a, miR-200b, miR-200c, and miR-203 expression were
decreased in this cell population (Figure 4F). Taken together,
the data provide compelling evidence for the coordinated regu-
lation of PRC2, PRC1, andmiRNAs in themaintenance of a differ-
entiated cellular state and inhibition of stem cell-like phenotypes.
In order to understand the functional biology of the miRNAs
identified in this study, we sought to identify global gene expres-
sion patterns and molecular pathways to which they might
contribute. We conducted gene expression microarray analyses
of DU145 and BT-549 cells transfectedwith control miRNA, miR-
101, miR-181a, miR-181b, miR-200a, miR-200b, miR-200c, or
miR-203. As shown in Table S2 and Table S3, EZH2-repressed
miRNAs targeted many predicted genes. When we analyzed
the miRNA-regulated genes using Molecular Concepts Maps
(MCM) (Tomlins et al., 2007b), as expected, molecular concepts
associated with thesemiRNAs were highly overlapping, showing
a high correlation to gene sets representing multiple cancers,
metastatic cancer processes, cancer survival, Polycomb Group
targets, and stem cell-related genes (Figure 4G; Table S4).
In order to further examine the molecular link between PRC1
and PRC2 activities, we generated DU145 cells stably overex-
pressing miR-200b and miR-203 (Figure S5A) and monitored
levels of BMI1 and RING2. BMI1 and RING2 were decreased in
miR-200b stable cells while only BMI1 was decreased in miR-
203 stable cells. In addition, uH2A, the histone modification
mediated by PRC1, was similarly decreased in both miR-200b-for concepts related to cancer (yellow), cancer survival (red), stem cell likenes
with ±SEM.
See also Figure S4, and Table S2, Table S3, and Table S4.and miR-203-expressing cells. Interestingly, BMI1, RING2, and
uH2A, as well as EZH2 and H3K27me3, were decreased in
miR-101 stable expressing DU145 cells (Figure 5A) suggesting
that prolonged knockdown of PRC2 components leads to
suppression of PRC1. Using cell count and Boyden chamber
invasion assays, we found that similar to miR-101, miR-200b
and miR-203 stably expressing cells grew more slowly and
were less invasive than vector-transfected cells (Figures 5B
and 5C). Intriguingly, coexpression of BMI1 or EZH2 (control)
without the 30 UTR both restored the proliferation and invasion
properties of DU145 cells despite the presence of miR-101,
miR-200b, or miR-203 (Figures 5B and 5C). Importantly, murine
xenograft experiments demonstrated that DU145 cells with
stable knockdownof PRC1proteinsBMI1 orRING2 (Figure S5B),
or expressing miR-181b (Figure S5C), miR-200b, or miR-203
grew more slowly than the vector control in vivo (p = 0.0001,
Figures 5D and 5E).
EZH2-Regulated miRNAs Inversely Correlate with PRC
Protein Levels in Prostate Cancer
Since miR-101, miR-181a, miR-181b, miR-200a, miR-200b,
miR-200c, and miR-203 appear to play an important role in
cancer progression, we next measured the endogenous expres-
sion levels of these miRNAs by qPCR analysis of a cohort of
benign prostate, localized, and metastatic prostate cancers in
which we had measured miR-101, miR-217, and EZH2 levels
previously (Varambally et al., 2008). As expected, miR-181a,
miR-181b, miR-200a, miR-200b, miR-200c, and miR-203 levels
were lowest in metastatic prostate cancer tissues, and highest in
benign prostate tissues (Figure 6A). In addition, immunoblot
analyses showed that BMI1, RING2, and uH2A, as well as
EZH2, but not RING1, were increased in metastatic prostate
cancer compared with benign tissues and localized cancer
samples (Figure 6B; Figure S6A). EZH2 levels were highly corre-
lated with BMI1, RING2, and H2A protein levels (Figure S6B),
further supporting a molecular link between PRC1 and PRC2
expression and activities during cancer progression. As ex-
pected, ChIP assays showed that H3K27me3-marked chromatin
occupied the miR-203 upstream region in metastatic prostate
cancer, but not in localized prostate cancer (PCA) (Figure S6C).
Similarly, DNA methylation of the miR-203 genomic region was
observed in localized and metastatic prostate cancer but not
benign prostate tissue (Figure 6C). Taken together, these data
suggest that EZH2-mediated epigenetic repression of miR-
181a, miR-181b, miR-200b, miR-200c, and miR-203 results in
an upregulation of PRC1 proteins BMI1 and RING2 and histone
code ubiquityl-H2A in advanced prostate cancer.
DISCUSSION
This study unravels the intricacies in the regulation of the poly-
comb protein complexes mediated by various miRNAs, and
substantiates the essential role played by PRC in cancer. We
demonstrated that increased PRC2 activity results in repression
of numerous miRNAs that are known to be important in thes (blue), and function of polycomb group (green). All bar graphs are shown
Cancer Cell 20, 187–199, August 16, 2011 ª2011 Elsevier Inc. 193
A B
D E
Figure 5. PRC2-Repressed miRNAs Inhibit
Tumor Growth
(A) DU145 cells stably overexpressing miR-101,
miR-200b, and miR-203 demonstrated repression
of EZH2, BMI1, or RING2, as well as decreased
H3K27me3 and ubiquityl-H2A (uH2A) levels.
(B and C) Coexpression of EZH2D30UTR or
BMI1D30UTR rescued cell proliferation (B), and
invasiveness (C) of DU145 cells stably overex-
pressing miR-101, miR-203, or miR-200b.
(D) Stably knocking down BMI1 or RING2 by
BMI1-specific shRNA (BMI1-sh3) or RING2-spe-
cific shRNA (RING2-sh1) decreased DU145 tumor
growth in mice. N = 8 for DU145 control (scra-
mble), BMI1-sh3, and RING2-sh1, respectively,
were used for the xenograft.
(E) Stable overexpression of miR-181b, miR-200b,
or miR-203 decreased DU145 tumor growth in
mice. DU145 miR-vector (N = 9), miR-NT (non-
targeting) (N = 8), miR-181b (N = 8), miR-200b
(N = 8), or miR-203 (N = 7) were used for the
xenograft experiment. DU145 stable pools were
injected subcutaneously.
All bar graphs are shown with ± SEM. See also
Figure S5.
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microRNAs Link PRC2 to PRC1maintenance of stem cell-like phenotypes in cancer cells. We
show that PRC2 epigenetically represses miR-181a, miR-181b,
miR-200b, miR-200c, and miR-203 expression by facilitating
H3K27me3 trimethylation at these loci, and that exogenous
overexpression of miR-181a, miR-181b, miR-200b, miR-200c,
and miR-203 inhibits a cancer phenotype in vitro. Furthermore,
miR-181b, miR-200b, and miR-203 overexpression suppressed
prostate tumor formation and growth in mouse xenografts.
Recently, several groups have also reported roles for miR-
200b, miR-200c, and miR-203 in controlling stem cell differenti-
ation (Yi et al., 2008), epithelial-to-mesenchymal transition (EMT)
(Park et al., 2008; Wellner et al., 2009), and cancer progression
(Faber et al., 2008; Shimono et al., 2009).
Here, we demonstrated that PRC1 proteins BMI1 and RING2
are direct targets of miR-181a, miR-181b, miR-200b, miR-
200c, and miR-203 in breast and prostate cancer. Furthermore,
we observed a significant negative correlation between PRC2
expression and miR-181a, miR-181b, miR-200b, miR-200c,
and miR-203, as well as a strong positive correlation between
EZH2, BMI1, and RING2 protein levels. Intriguingly, earlier
studies suggested a discrepancy between BMI1 protein and194 Cancer Cell 20, 187–199, August 16, 2011 ª2011 Elsevier Inc.RNA levels in prostate tissues, as protein
levels were increased while RNA levels
were decreased during prostate cancer
progression (Varambally et al., 2005). It
is possible that regulation of PRC
proteins occurs at both transcriptional
and posttranscriptional levels by sepa-
rate mechanisms. We provide evidence
that EZH2-regulated microRNAs con-
tribute to the maintenance of a differenti-
ated cellular state, and that miR-181a,
miR-181b, miR-200b, miR-200c, andmiR-203 function as tumor suppressors during prostate cancer
progression.
Interestingly, several recent studies have reported similar
microRNA-protein regulatory networks that play critical roles in
cancer. In one study, the RAS proto-oncogene was shown to
be coordinately regulated by the let-7 family of miRs (Johnson
et al., 2005). Likewise, the miR-15a–miR-16-1 cluster, located
on chr13q14, was proposed to serve as a tumor suppressor in
prostate tissue by regulating levels of cancer-related genes
such as BCL2, CCND1, and WNT3A (Bonci et al., 2008).
Recently, Poliseno et al. (2010) reported a proto-oncogenic
miRNA-dependent network in prostate cancer progression in
which the miR-106b25 cluster regulates PTEN expression
and cooperates with MCM7 in cellular transformation. These
studies, along with our present study, strongly suggest that dys-
regulation of miRNA and target protein networks may contribute
to cancer development.
Here, we propose a model for a coordinated PRC2-PRC1
oncoprotein axis, and epigenetic link between H3K27me3
and ubiquityl-H2A, mediated by PRC2-regulated miRNAs (Fig-
ure 7). Recently, Iliopoulos et al. (2010) reported that miR-200b
AB C
Figure 6. Coordinated Expression of PcG Proteins and PRC Regulatory miRNAs in Prostate Cancer Progression
(A) Expression of indicated miRs as assessed by q-PCR in benign prostate, clinically localized prostate cancer and metastatic prostate cancer tissues. Data for
EZH2, miR-217, and miR-101 were reported previously (Varambally et al., 2008) and displayed here for comparison (Student’s t test).
(B) Immunoblot analysis of EZH2,BMI-1,RING2,RING1, andubiquityl-H2A inbenign prostate, clinically localizedprostate cancer, andmetastatic prostate cancer.
(C) Bisulfite sequencing analysis of the miR-203 genomic region revealed cancer-specific DNA methylation in a region proximal to miR-203 in prostate cancer
tissues.
All bar graphs are shown with ± SEM. See also Figure S6.
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microRNAs Link PRC2 to PRC1regulates PRC2 protein SUZ12 in amanner similar to that of miR-
101, lending further support for microRNA-mediated PRC
activity during cancer progression. These findings offer multiple
targets for therapeutic interventions in the treatment of aggres-
sive cancers (Garzon et al., 2010).
EXPERIMENTAL PROCEDURES
Cell Lines
Breast cancer cell line BT-549 was grown in RPMI 1640 (Invitrogen, Carlsbad,
CA) with 0.023 IU/ml insulin and 10% FBS (Invitrogen) in 5% CO2 cell cultureincubator; breast cancer cell line SKBr3 was grown in RPMI 1640 (Invitrogen)
with 10% FBS (Invitrogen) in 5% CO2 cell culture incubator; and prostate
cancer cell line DU145 was grown in MEM with 10% FBS in 5% CO2 cell
culture incubator. Immortalized breast cell lines HME and H16N2 were grown
in F-12 Nutrient Mixture with 5mg/ml Insulin (Sigma, St. Louis, MO), 1 mg/ml
Hydrocortisone (Sigma), 10 ng/ml EGF (Invitrogen), 5 mM Ethanolamine
(Sigma), 5 mg/ml Transferrin (Sigma), 10 nM Triiodo Thyronine (Sigma),
50 nM Sodium Selenite (Sigma), 10 mM HEPES (Invitrogen) and 50 unit/ml
Penstrep (Invitrogen), 10% CO2. The PrEC (Lonza, Conshohocken, PA) and
RWPE (ATCC, Manassas, VA) cells were grown in their respective medium
as specified by the suppliers. miR-181b, miR-200b, and miR-203 overex-
pression constructs were obtained from Openbiosystems (Huntsville, AL).Cancer Cell 20, 187–199, August 16, 2011 ª2011 Elsevier Inc. 195
Figure 7. A Proposed Model Role for micro-
RNAs in Regulating PRCs
Specifically, PRC2 is molecularly linked to PRC1
via a set of regulatory miRs.
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microRNAs Link PRC2 to PRC1Lentiviruses were generated by the University of Michigan Vector Core. BMI1,
RING2 and control shRNA lentivirus were obtain from Sigma. Prostate cancer
cell line DU145 was infected with lentiviruses expressing BMI1 shRNA, RING2
shRNA, miR-181b, miR-200b, and miR-203 or controls only, and stable cell
lines were generated by selection with 300 mg/ml puromycin (Invitrogen).
Benign and Tumor Tissues
In this study, we utilized tissues from clinically localized prostate cancer
patients who underwent radical prostatectomy as a primary therapy between
2004 and 2006 at the University of Michigan Hospital. Samples were also used
from androgen-independent metastatic prostate cancer patients from a rapid
autopsy program described previously (Tomlins et al., 2005, 2007a). The
detailed clinical and pathological data are maintained in a secure relational
database. This study was approved by the Institutional Review Board at the
University of Michigan Medical School. Informed consent was also obtained
from all subjects through the Institutional Review Board at the University of
Michigan Medical School. Both radical prostatectomy series and the rapid
autopsy program are part of the University of Michigan Prostate Cancer
Specialized Program of Research Excellence Tissue Core.
Illumina microRNA Profiling
Total RNA (500 ng) from each sample was labeled and hybridized on the
Human v2microRNA Expression BeadChips (Illumina, San Diego, CA) accord-
ing to the manufacturers recommendations. BeadChips were scanned with
the Illumina iScan Reader. Data were then average median normalized before
generating differential expression values between treated and control
samples.
microRNA Transfection, AntagomiR Transfection, and Small RNA
Interference
Knockdown of EZH2 or Dicer was accomplished by RNA interference using
siRNA duplexes (Dharmacon, Lafayette, CO) as previously described (Varam-
bally et al., 2002). Precursors of respective microRNAs, antagomiRs and nega-
tive controls were purchased from Ambion (Austin, TX). Transfections were
performed with oligofectamine (Invitrogen). EZH2 siRNA duplexes sequences,
(duplex 1: GAGGTTCAGACGAGCTGAT; duplex 2: AGACTCT GAATGCA
GTTGC).
miR Reporter Luciferase Assays
The 50 bp of wild-type or mutant 30 UTR of BMI1 and RING2 containing the
predicted miR-181a,b, miR-200b,c or miR-203 binding sites (as described in
Figures S2C–S2F) were cloned into the pMIR-REPORT miRNA Expression
Reporter Vector (Ambion). BT-549 cells were transfected with miRNAs or
controls and then cotransfected with wild-type 30 UTR-luc or mutant 30 UTR-
luc, as well as pRL-TK vector as internal control for luciferase activity. After
48 hours of transfection, the cells were lysed and luciferase assays were con-
ducted using the dual luciferase assay system (Promega, Madison, WI). Each
experiment was performed in triplicate. Drug Treatment.
BT-549 and DU145 cells were treated with 5 mM 5-aza-20-deoxycytidine
(5-aza-dC) for 6 days (fresh media change containing the drug was performed196 Cancer Cell 20, 187–199, August 16, 2011 ª2011 Elsevier Inc.every other day) and/or 1mM suberoylanilide
hydroxamic acid (SAHA) for 2 days. DU145 cells
were treated with 2.5 or 5 mM deazaneplanocin A
(DZNep) for 2 or 3 days followed by RNA extraction
or chromatin immunoprecipitation.
Cell Proliferation Assay and Basement
Membrane Matrix Invasion Assays
Invasive breast cancer cell BT-549 and prostate
cancer cell DU145 were transfected with miRNAs
or controls. The cell proliferation and invasionassays were performed as described (Cao et al., 2008; Kleer et al., 2003; Var-
ambally et al., 2008; Yu et al., 2007b).
Soft Agar Colony Formation Assays
A 50 ml base layer of agar (0.6% Agar in DMEM with 10% FBS) was allowed to
solidify in a 96-well flat-bottom plate prior to the addition of a 75 ml miRNAs or
control-transfected or stable DU145 cell suspension containing 4000 cells in
0.4% Agar in DMEM with 10% FBS. The cell containing layer was then solid-
ified at 4C for 15min prior to the addition of 100 ml of MEMwith 5% FBS. Colo-
nies were allowed to grow for 21 days followed by counting and imaging under
a light microscope.
Spheres Culture
Spheres culture was performed as described (Dontu et al., 2003; Yu et al.,
2007a). Briefly, cells (1000 cells/ml) were cultured in suspension in serum-
free DMEM-F12 (Invitrogen), supplemented with B27 (1:50, Invitrogen),
20 ng/ml EGF (BD Biosciences), 0.4% bovine serum albumin (Sigma), and
4 mg/ml insulin (Sigma). To propagate spheres in vitro, spheres were collected
by gentle centrifugation, dissociated to single cells as described (Dontu et al.,
2003; Yu et al., 2007a), and then cultured to generate prostatospheres of the
next generation. Spheres larger than 50 mm were counted.
Gene Expression Profiling
Expression profiling was performed using the Agilent Whole Human Genome
Oligo Microarray (Santa Clara, CA) according to the manufacturer’s protocol.
BT-549 and DU145 cells were transfected with miRNAs or negative control for
precursor microRNA. Over- and underexpressed signatures were generated
by filtering to include only features with significant differential expression
(Log ratio, p < .01) in all hybridizations and 2-fold average over- or under-
expression (Log ratio). Gene expression data are deposited into GEO
(GSE26996).
Gene Set Enrichment Analysis
Molecular Concept Map (MCM) analysis was performed using gene list of
putative targets to search for all concepts available in the Oncomine database
as previously described (Yu et al., 2007c). Representative concepts with signif-
icant enrichment (p < 0.001) were displayed as a network (Figure 4G; Table S4).
Prostate Tumor Xenograft Model
All procedures involving mice were approved by the University Committee on
Use and Care of Animals (UCUCA) at the University of Michigan and conform
to their relevant regulatory standards. Five-week-old male nude athymic
BALB/c nu/nu mice (Charles River Laboratory, Wilmington, MA) were used
for examining tumorigenicity. To evaluate the role of BMI1 and RING2 knock-
down, or miR-181b, miR-200b, and miR-203 overexpression in tumor forma-
tion, the DU145 stably overexpressing BMI1 shRNA, RING2 shRNA, scramble
shRNA, miR-181b, miR-200b, miR-203, nontargeting miR or vector control
cells were propagated and 5 3 106 cells were inoculated subcutaneously
into the dorsal flank of mice (n = 7 for miR-203, n = 9 for vector control, and
n = 8 for Scramble, BMI1-sh3, RING2-sh1, miR-181b, miR-200b, and miR-NT,
Cancer Cell
microRNAs Link PRC2 to PRC1respectively). Tumor size was measured every week, and tumor volumes were
estimated using the formula (p/6) (L3W2), where L = length of tumor andW =
width.
Bisulfite Modification and Methylation-Specific PCR of miR-203
in Prostate Tissues
Bisulfite conversion was carried out using EZ DNA methylation gold kit (Zymo
Research Corporation, Orange, CA) according to manufacturer’s instructions.
Purified DNA (2 ml) was used as template for PCRs with primers (Integrated
DNA Technologies Inc., San Diego, CA) and synthesized according to bisul-
fite converted DNA sequences for the regions of interest using the Meth-
primer software (Li and Dahiya, 2002). The PCR product was gel purified
and cloned into pCR4 TOPO TA sequencing vector (Invitrogen, Carlsbad,
CA). Plasmid DNA isolated from ten colonies from each sample was
sequenced by conventional Sanger Sequencing (University of Michigan
DNA Sequencing Core). The ‘‘BIQ Analyzer’’ (Bock et al., 2005) online tool
was used to calculate the methylation percentage and to generate the bar
graphs.
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accession code GSE26996.
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